

# Sleep apnea key facts and figures

# What is sleep-disordered breathing (SDB)?

SDB describes a number of nocturnal breathing disorders:

- Obstructive sleep apnea (OSA)
- Central sleep apnea (CSA)
- Nocturnal hypoventilation
- Cheyne-Stokes respiration (CSR)

# What is obstructive sleep apnea (OSA)?

- The most common form of SDB
- A partial or complete collapse of the upper airway caused by relaxation of the muscles controlling the soft palate and tongue
- People may experience apneas, hypopneas and flow limitation
  - Apnea: a cessation of airflow for ≥10 seconds
  - Hypopnea: a decrease in airflow lasting ≥10 seconds with a 30% reduction in airflow and at least a 3% oxygen desaturation from baseline
  - Flow limitation: narrowing of the upper airway and an indication of an impending upper airway closure







Normal

Flow limitation (airway narrowing)

**Apnea** (airway closed)

# Classification of sleep apnea

Apnea-hypopnea index (AHI)

- Number of apneas and/or hypopneas per hour of sleep (or study time)
- Reflects the severity of sleep apnea

AHI: <5	Normal range
AHI: 5 to <15	Mild sleep apnea
AHI: 15 to <30	Moderate sleep apnea
AHI: ≥30	Severe sleep apnea

#### Prevalence of sleep apnea

- An estimated 1 billion people have sleep apnea worldwide<sup>1</sup>
- Approximately 85.6 million adults in the U.S. have obstructive sleep apnea, and about 68.5 million are undiagnosed<sup>2</sup>
- In the US, about **49 million** have mild OSA, and **19 million** have moderate OSA<sup>2</sup>
- The prevalence of moderate-to-severe sleep disordered breathing is 23.4% in women and 49.7% in men<sup>3</sup>
- Incidence of OSA is 3.5x higher in post-menopausal women<sup>4</sup>
- More than 80% of people living with OSA are undiagnosed and unaware they have the condition<sup>1</sup>

## Prevalence of Sleep Apnea in Comorbidities



## Signs and symptoms of sleep apnea

- · Lack of energy
- Morning headaches
- Frequent nighttime urination
- Depression, irritability or anxiety
- Excessive daytime sleepiness (EDS)
- Nighttime gasping, choking or coughing
- Gastroesophageal reflux (GE reflux)
- Irregular breathing during sleep (e.g. snoring)

# Increased risk factors for sleep apnea

- Obesity (BMI > 30)
- Diagnosis of high blood pressure
- Large neck circumference (>17" men; 16" women)
- Excessive use of alcohol or sedatives
- Upper airway or facial abnormalities
- Smoking
- · Family history of OSA
- Endocrine and metabolic disorders

# Mortality links

- People with OSA who remain untreated face a significantly higher risk of death—more than 3 times greater than those using CPAP therapy<sup>14</sup>
- A 2025 meta-analysis of over 1 million patients showed that CPAP therapy reduces all-cause mortality by 37%<sup>15</sup>
- Patients who adhere to CPAP therapy experience significantly better survival outcomes—up to a 55% reduction in cardiovascular mortality, and a consistent reduction in major adverse cardiovascular events (MACE) with higher nightly usage<sup>16</sup>

#### Stroke risks

- OSA patients have more than twice the risk of suffering a stroke<sup>17</sup>
- 70% of stroke patients have OSA10

#### Healthcare costs

- The estimated cost of undiagnosed OSA in the US was nearly \$150 billion in 2015<sup>18</sup>
- The total health cost per patient declined \$3,418 in year 1 of PAP usage in adherent patients and continued to decrease by \$1,179 in year 2<sup>19</sup>
- Consistent use of PAP therapy over 2 years is associated with decreased healthcare resource utilization in patients with OSA and type 2 diabetes<sup>19</sup>
- Obstructive sleep apnea patients who were adherent with positive airway pressure (PAP) therapy had a 25.7% reduction in health care utilization<sup>20</sup>
- An estimated \$2,282 USD were saved in healthcare utilization over 2 years for patients that are adherent to PAP, as compared to non-adherent patients<sup>21</sup>

## Treatment of OSA with CPAP

- OSA patients who continue therapy throughout the first year have 39% increased chances of survival,
  25% reduced risk of developing hypertension, and
  23% reduced risk for developing heart failure<sup>22</sup>
- Patients with mild OSA found significant improvements in quality of life after being treated with CPAP<sup>23</sup>
- OSA patients who are adherent to PAP therapy have fewer ER visits and hospitalizations 1 and 2 years after starting PAP therapy<sup>24</sup>
- PAP usage by patients who have OSA and COPD was associated with reduced all-cause hospitalizations and emergency room visits, severe acute exacerbations, and healthcare costs<sup>25</sup>
- OSA patients who use CPAP therapy for at least 2–3 hours/night saw a statistically significant benefit in hospitalization reduction<sup>26</sup>

<sup>26</sup> Malhotra, A. et al. Annals of ATS 2023



 $<sup>{\</sup>bf 1} \ \ \mathsf{Benjafield} \, \mathsf{et} \, \mathsf{al.} \, \mathsf{Lancet} \, \mathsf{Respir} \, \mathsf{Med} \, \mathsf{2019}$ 

<sup>2</sup> Malhotra, A. et al. Sleep 2024

 $<sup>{\</sup>bf 3}\ \ \mathsf{Heinzer\,R.\,et\,al.\,Lancet\,Respir\,Med\,2015}$ 

 $<sup>\</sup>textbf{4} \hspace{0.2cm} \textbf{Bruyneel}, \textbf{M.} \, \textbf{et al.} \, \textbf{Maturitas} \, \textbf{2015}$ 

<sup>5</sup> Mokhlesi et al. Proc Am Thorac Soc 2008

 $<sup>\</sup>textbf{6} \hspace{0.2cm} \textbf{American Academy of Sleep Medicine 2014}$ 

 $<sup>{\</sup>bf 7} \quad \hbox{Chukwu}, \hbox{E.\,N.}, \hbox{et al.\,Heart Failure Reviews} \, 2024$ 

<sup>8</sup> Khosla, S., et al. Heart Rhythm 2024

<sup>9</sup> Andayeshgar et al. Sleep Science Practice 2022

**<sup>10</sup>** Bravata, D. M., et al. Sleep 2021

<sup>11</sup> Kong et al. Sci Rep 2017

<sup>12</sup> Oscullo et al. J Clin Med 2019

<sup>13</sup> Marin et al. AJRCCM Suppl ATS Abstract 201714 Dodds, S. et al. ERJ Open Research 2020

 $<sup>\</sup>textbf{15} \ \, \mathsf{Benjafield}, \mathsf{et\,al}. \, \mathsf{Lancet\,Rep\,Med\,2025}$ 

<sup>16</sup> Gervès-Pinquié, C., et al. AJRCCM 2022

<sup>17</sup> Dong, J. Y., et al. Atherosclerosis 201318 American Academy of Sleep Medicine, 2016

<sup>19</sup> Sterling et al. AJRCCM 2022

 $<sup>\</sup>textbf{20} \;\; \text{Walter R et al. Sleep Med 2017}$ 

<sup>21</sup> Sterling, KL. Et al. J Clin Sleep Med 2022

**<sup>22</sup>** Pepin et al. CHEST 2022

<sup>23</sup> Wimms et al. Lancet 2020

<sup>24</sup> Cole, KV. et al. ATS Abstract 2022

<sup>25</sup> Sterling et al. AJRCCM 2022